If you have not already registered for Full Text Access to The Journal, then visit our registration page.
Many supplements are available to the general public for a limited time on our SuppleNet page.


VOLUME 60   1999   SUPPLEMENT 10

Articles

3 Introduction. What Makes an Antipsychotic Atypical? Stephen M. Stahl, M.D., Ph.D.
[PDF]

5 Receptor Pharmacology of Neuroleptics: Relation to Clinical Effects. Elliott Richelson, M.D.
[Abstract] [PDF]

15 D2 and 5-HT2 Receptor Effects of Antipsychotics: Bridging Basic and Clinical Findings Using PET. Gary Remington, M.D., Ph.D., F.R.C.P.C., and Shitij Kapur, M.D., Ph.D., F.R.C.P.C.
[Abstract] [PDF]

20 Pharmacologic and Pharmacokinetic Considerations in Choosing an Antipsychotic. Larry Ereshefsky, Pharm.D., F.C.C.P., B.C.C.P.
[Abstract] [PDF]

31 Selecting an Atypical Antipsychotic by Combining Clinical Experience With Guidelines From Clinical Trials. Stephen M. Stahl, M.D., Ph.D.
[Abstract] [PDF]

42 Does Loxapine Have “Atypical” Properties? Clinical Evidence. William M. Glazer, M.D.
[Abstract] [PDF]

47 Low-Dose Loxapine in the Treatment of Schizophrenia: Is It More Effective and More “Atypical” Than Standard-Dose Loxapine? Herbert Y. Meltzer, M.D., and Karuna Jayathilake, M.A.
[Abstract] [PDF]

52 The Role of Typical and Atypical Antipsychotic Medications in the Management of Agitation and Aggression. Peter F. Buckley, M.D.
[Abstract] [PDF]